Account for EUBIJ content access
Login / Register
Login / Register
— Latest update: May 2022 —
With an ever-increasing number of bio-ventures and the establishment of a new ecosystem in the Japanese biotech field, this sector offers many opportunities for European SME companies. Through industrial, academic, government and international collaboration, various programs are being promoted and implemented. Due to Japan’s population aging and the resulting health issues, the pharmaceutical sector remains an especially attractive market, as evidenced by the high number of deals between European investors and Japanese biopharma in 2021.
JBA, 2021 Activity Report
EU-Japan Centre, Report : Japan Bioventures Landscape, 2018
JETRO, Life Sciences: Attractive Sectors, 2021
Table of Contents
The EU-Japan Centre currently produces 5 newsletters :
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.
The EU-Japan Centre’s activities are subject to the allocation of a Grant Agreement by the European Commission for 2024-2026
